ProMetic Life Sciences Inc announced that its wholly owned subsidiary ProMetic BioSciences Ltd has signed a contract with GlaxoSmithKline (GSK) to provide GSK access to ProMetic's unique affinity purification technology. Financial terms were not disclosed.

Under the agreement, ProMetic will develop affinity materials and purification process steps for the isolation and purification of therapeutic proteins of interest to GSK. This will provide GSK with state-of-the-art purification materials and technology, which enable accelerated product and process development, high product yields, optimal process economics, and regulatory compliance, the company release said.

Mimetic Ligands will be developed for the purification of target proteins using ProMetic's Intelligent Combinatorial Libraries discovery platform. Selected ligands will be attached to Prometic's support materials and manufactured to the high quality standards required for the production of biotherapeutic products.

"This agreement marks an important turning point for ProMetic" commented Steve Burton, executive vice president and CSO of ProMetic BioSciences. "We have enjoyed many successes with individual custom adsorbent development programs, but this is the first time we have entered into an agreement where ProMetic will collaborate on the development of purification processes on an on-going basis," he added further.

"This latest agreement emphasizes the increasing adoption of ProMetic's purification technology by world-leading pharmaceutical companies, underlining the benefits of ProMetic's technology for cost-effective manufacture of protein therapeutics," added Dr. Burton.